Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Drug Firms Question Investment in UK
- LONDON (Reuters UK) - Global drugmakers have started to question their investment in Britain, following a government decision to scrap a 50-year-old drug pricing scheme, the outgoing head of the country's industry body said on Thursday. Nigel Brooksby, president of the Association of the British ...
- News items 2008-04-30
- Sanofi Hit By Generic Plavix Threat in Europe
- By Ben Hirschler LONDON (Reuters) - French drugmaker Sanofi-Aventis SASY, which briefly encountered generic competition to its second-biggest product Plavix in the United States in 2006 and 2007, now faces a similar threat in Europe. Schweizerhall SWHN, a Swiss generic drug company, said...
- News items 2008-05-09
- Tableting and Filling Go "Inside the Box"
- As the move to increasingly selective - and potent - formulations continues, drug manufacturers are looking for new ways to protect operators from exposure to extremely potent ingredients while maintaining production efficiency. Traditionally, workers have been shielded by personnel protective equipment PPE, such as uncomfortable "space suits" that take time...
- White papers
- Manufacturing Phil: A Drug's Life
- A Pfizer public education campaign and its cute mascot are praiseworthy, but neglect to mention the key stage in a drug's life. What will it take to make manufacturing a hot button issue and to better educate the public? Given the current consumer and media backlash against drug makers, there's...
- White papers
- Cost Cutting Boosts Novartis Q1 Profit
- By Sam Cage ZURICH (Reuters) - First-quarter net profit at Swiss drugmaker Novartis AG NOVN rose 10 percent to $2.31 billion, helped by cost cuts and the weak dollar, easily beating forecasts and sending its shares up more than 5 percent....
- News items 2008-04-21
- Glaxo Gets an FDA Warning... With Teeth
- Well before Vytorin became a cause célèbre -- which is to say, about a year ago -- GlaxoSmithKline's Avandia was the drug getting slapped around by critics for, in that case, possible heart problems that had possibly been downplayed or ignored. That case, which led to new warnings on the...
- Blog posts 2008-04-12
- Pfizer Leads in Layoffs While Drug Prices Soar
- Big Pharma continues to lend new meaning to the phrase "doing more with less," because while the industry seems to get smaller every day, drugmakers are still pushing through big price increases on their leading products. Over at Pharmalot, Ed Silverman provides a helpful roundup tracking the...
- Blog posts 2008-04-10
- Oxymoron No More: The Potential of Nonprofit Drug Companies to Deliver on the Promise of Medicines for the Developing World
- Although some pharmaceutical company efforts to develop and distribute drugs in developing countries have been successful, many fall short of meeting needs in resource-poor nations. The paper discusses the concept of a nonprofit pharmaceutical company dedicated to developing and distributing drugs for diseases endemic in developing countries. Using the experience...
- White papers 2005-08-01
- New Federal Guidelines for Physician- Pharmaceutical Industry Relations: The Politics of Policy Formation
- To evaluate the impact of their responses, this report compares the draft, the changes requested by industry and organized medicine, and the final Guidance document. This draft Guidance questioned the legality of many arrangements heretofore left to the discretion of physicians and drug companies, including industry-funded educational and research grants,...
- White papers 2005-08-01
- Drug Wholesaling Moves to Fee for Service: Observations and Implications
- There has been much movement by drug companies in altering wholesaler buying patterns through various inventory agreements, with a noticeable majority already having some agreement in place. There has been real movement by drug manufacturers to change the profit models of their wholesalers through a de-emphasis on channel incentives. The...
- White papers 2004-01-14
- For and Against: Direct to Consumer Advertising Is Medicalising Normal Human Experience: For
- In direct to consumer advertising, drug companies target advertisements for prescription drugs directly at the public. This paper argues that this type of advertising risks medical sing normal human conditions, with the drug companies raking in increasingly healthy profits. The paper argues that, through advertising, drug companies can enable patients...
- White papers 2002-04-13
- Will Online Rx Get Easier to Swallow?
- As pharmaceuticals struggle to get doctors to take their medicine, they ignore the valuable branding resources available on the web. Most pharmaceutical branding rarely goes beyond the trademarked name, at least for patients. But among the professional medical community, drug companies embrace the scope for building a more complete brand...
- White papers 2002-01-07
Additional Resources
- Rx drug distributor agrees to pay penalties
- One of the nation's largest distributors of pharmaceutical drugs has agreed to settle allegations that it violated the law when it failed to report suspicious drug sales to the DEA out of several distribution facilities, including one in Utah. McKesson Corp. has agreed to pay $13.25 million...
- Articles 2008-05-08
- Public Media Works Teams With Fuqua Films on Book Option for 'Without a Badge'
- Public Media Works, Inc. (OTCBB: PUBM), afilm, music and television entertainment and digital media company,announced today that it has entered into an agreement with stylized filmdirector Antoine Fuqua's, Fuqua Films, Inc., to option the life story ofJerry Speziale 'Without a Badge.' 'Without a Badge: Undercover in the World's Deadliest CriminalOrganization'...
- Articles 2008-05-08
- Critical Outcome Technologies Inc. Announces Granting of European Patents for Acute Myelogenous Leukemia Drug Candidates
- Critical Outcome Technologies Inc. (TSX VENTURE: COT), announced today that patents to its novel drug candidates for the treatment of Acute Myelogenous Leukemia AML have recently been granted by the European Patent Office. The patents have been granted under European patent numbers 1 551 824 and 1 542 989 and...
- Articles 2008-05-07
- Pipex Pharmaceuticals Announces Notice of Allowance of U.S. Patent for Oral TTM for Alzheimer's Disease
- Pipex Pharmaceuticals, Inc. (AMEX: PP), aspecialty pharmaceutical company developing innovative late-stage drugcandidates for the treatment of neurologic and autoimmune diseases,announced today that it has received a notice of allowance from the UnitedStates Patent and Trademark Office for exclusively licensed U.S. patentapplication Ser. No. 11/057.353 containing claims covering the use ofthiomolybdates...
- Articles 2008-05-07
- Transdermal Drug Delivery — Technologies, Markets, and Companies
- DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reportinfo.asp?report_id=39074) has announced the addition of Transdermal Drug Delivery -- Technologies, Markets, and Companies to their offering. This report deals with transdermal drug delivery -- an approach used to deliver drugs through the skin for therapeutic use as an alternative to oral,...
- Articles 2008-05-07
- Cell Therapy Playing an Increasingly Important Role in The Practice of Medicine
- DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reportinfo.asp?report_id=39071) has announced the addition of Jain PharmaBiotech "Cell Therapy - Technologies, Markets and Companies" to their offering This report describes and evaluates cell therapy technologies and methods, which have already started to play an important role in the practice of medicine....
- Articles 2008-05-07
- Osteologix IND for NB S101 for Osteoporosis Accepted by FDA
- SAN FRANCISCO -- Osteologix, Inc. (OLGX.OB), a specialty biopharmaceutical company, today announced that the U. S. Food and Drug Administration FDA has accepted its Investigational New Drug IND application for its lead development candidate NB S101 strontium malonate, for the treatment and prevention of osteoporosis. NB S101, a dual acting...
- Articles 2008-05-07
- Acucela Files Investigational New Drug Application
- ---- Orally-available Small Molecule for Dry Form of AMD ---- BOTHELL, Wash. -- Acucela Inc., a clinical-stage biotechnology company focused on developing therapies for blinding eye diseases, announced today that it has filed an investigational new drug IND application to conduct a Phase 1 clinical trial for its...
- Articles 2008-05-07
- << Previous
- page 1 of 1
- Next >>
Content Types
Premier Vendor Content Whitepapers, webcasts & resources from our Power Center Sponsors
